These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 36617999)
1. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy. Chen T; Xu J; Zhu L; Yan D Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999 [TBL] [Abstract][Full Text] [Related]
2. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of Ovarian Cancer. Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905 [TBL] [Abstract][Full Text] [Related]
3. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas. Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides. Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963 [TBL] [Abstract][Full Text] [Related]
5. Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy. Xu J; Chen T; Sun T; Yu C; Yan D; Zhu L Biomater Sci; 2022 Nov; 10(22):6601-6613. PubMed ID: 36250610 [TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2 expression in cell lines breast cancer and death program. Janaghard MS; Soleimani S; Movafagh A; Motallebi M; Mousavi SA; Moghadam AAS; Moghadam VE; Khosravi A; Mirzaei HR; Mousavi SAR; Aziziaram Z; Sun C Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):277-285. PubMed ID: 38279418 [TBL] [Abstract][Full Text] [Related]
8. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246 [TBL] [Abstract][Full Text] [Related]
9. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012 [TBL] [Abstract][Full Text] [Related]
11. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides. Lo YL; Liu Y PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737 [TBL] [Abstract][Full Text] [Related]
12. Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells. Pan Q; Nie C; Hu Y; Yi J; Liu C; Zhang J; He M; He M; Chen T; Chu X ACS Appl Mater Interfaces; 2020 Jan; 12(1):400-409. PubMed ID: 31815420 [TBL] [Abstract][Full Text] [Related]
13. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides. Delihas N Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717 [TBL] [Abstract][Full Text] [Related]
15. Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer. Heger Z; Polanska H; Krizkova S; Balvan J; Raudenska M; Dostalova S; Moulick A; Masarik M; Adam V Colloids Surf B Biointerfaces; 2017 Feb; 150():131-140. PubMed ID: 27907860 [TBL] [Abstract][Full Text] [Related]
16. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990 [TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421 [TBL] [Abstract][Full Text] [Related]
18. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy. Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pakunlu RI; Cook TJ; Minko T Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953 [TBL] [Abstract][Full Text] [Related]
20. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Loomis R; Carbone R; Reiss M; Lacy J Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]